


Synephrine hemitartrate

Cat. No.:	HY-N0132B
CAS No.:	16589-24-5
Molecular Formula:	C ₉ H ₁₃ NO ₂ ·1/2C ₄ H ₆ O ₆
Molecular Weight:	242.26
Target:	Adrenergic Receptor; Endogenous Metabolite
Pathway:	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Synephrine (Oxedrine) hemitartrate, an alkaloid, is an α -adrenergic and β -adrenergic agonist derived from the Citrus aurantium. Synephrine hemitartrate is a sympathomimetic compound and can be used for weight loss ^{[1][2]} .								
In Vivo	<p>Synephrine (1 mg/kg; oral gavage; for 8 days; PVL and BDL rats) significantly ameliorates the hyperdynamic state in both PVL and BDL rats. The portal venous pressure in PVL and BDL rats, portal tributary blood flow and cardiac index are significantly reduced, while mean arterial pressure and systemic as well as portal territory vascular resistance are enhanced by treatment of Synephrine^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Portal vein ligation (PVL) or bile duct ligation (BDL) rats^[2].</td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg per 12 hours</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; for 8 days</td> </tr> <tr> <td>Result:</td> <td>The portal venous pressure in PVL and BDL rats, portal tributary blood flow and cardiac index were significantly reduced, while mean arterial pressure and systemic as well as portal territory vascular resistance were enhanced.</td> </tr> </table>	Animal Model:	Portal vein ligation (PVL) or bile duct ligation (BDL) rats ^[2] .	Dosage:	1 mg/kg per 12 hours	Administration:	Oral gavage; for 8 days	Result:	The portal venous pressure in PVL and BDL rats, portal tributary blood flow and cardiac index were significantly reduced, while mean arterial pressure and systemic as well as portal territory vascular resistance were enhanced.
Animal Model:	Portal vein ligation (PVL) or bile duct ligation (BDL) rats ^[2] .								
Dosage:	1 mg/kg per 12 hours								
Administration:	Oral gavage; for 8 days								
Result:	The portal venous pressure in PVL and BDL rats, portal tributary blood flow and cardiac index were significantly reduced, while mean arterial pressure and systemic as well as portal territory vascular resistance were enhanced.								

REFERENCES

- [1]. Thomas JE, et al. STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: a case report and review of the literature. *Tex Heart Inst J.* 2009;36(6):586-90.
- [2]. Huang YT, et al. Hemodynamic effects of synephrine treatment in portal hypertensive rats. *Jpn J Pharmacol.* 2001 Feb;85(2):183-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA